Wave Life Sciences Ltd (WVE) — Cash Flow-to-Debt Ratio
Wave Life Sciences Ltd (WVE) has a Cash Flow-to-Debt Ratio of -0.83x as of March 2026, meaning its operating cash flow of $-59.55 Million could theoretically repay -1% of its total liabilities ($71.81 Million) in one year. See WVE free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Wave Life Sciences Ltd Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Wave Life Sciences Ltd across 13 annual periods. For the full cash flow conversion analysis, see Wave Life Sciences Ltd operating cash flow efficiency.
Annual Cash Flow-to-Debt Ratio for Wave Life Sciences Ltd (2013–2025)
Year-by-year debt coverage analysis for Wave Life Sciences Ltd. Check WVE cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.67x | $-187.49 Million | $112.27 Million | ▼ -57.8% |
| 2024 | -1.06x | $-151.03 Million | $142.69 Million | ▼ -1181.8% |
| 2023 | -0.08x | $-19.43 Million | $235.32 Million | ▲ +87.6% |
| 2022 | -0.67x | $-127.78 Million | $191.48 Million | ▼ -30.9% |
| 2021 | -0.51x | $-88.99 Million | $174.51 Million | ▲ +17.1% |
| 2020 | -0.62x | $-115.98 Million | $188.59 Million | ▲ +30.5% |
| 2019 | -0.89x | $-188.23 Million | $212.64 Million | ▼ -761.9% |
| 2018 | -0.10x | $-22.86 Million | $222.59 Million | ▲ +94.8% |
| 2017 | -1.99x | $-83.67 Million | $42.03 Million | ▼ -87.1% |
| 2016 | -1.06x | $-31.87 Million | $29.95 Million | ▼ -1.4% |
| 2015 | -1.05x | $-12.53 Million | $11.93 Million | ▲ +78.4% |
| 2014 | -4.86x | $-4.43 Million | $911.00K | ▼ -1279.8% |
| 2013 | -0.35x | $-3.55 Million | $10.09 Million | — |